Glycomine, Inc.
Clinical trials sponsored by Glycomine, Inc., explained in plain language.
-
New hope for rare disease: experimental drug targets PMM2-CDG
Disease control CompletedThis study tested an experimental drug called GLM101 in 27 people with PMM2-CDG, a rare genetic condition that causes problems with balance and movement. Participants received different doses of the drug intravenously over 24 weeks. The main goal was to see if the drug improves c…
Phase: PHASE2 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Researchers track rare disease PMM2-CDG to unlock clues for future treatments
Knowledge-focused CompletedThis study is gathering medical information from 120 people with PMM2-CDG, a rare genetic disorder. Researchers will track growth, organ function, and development over time. The goal is to better understand the disease and help design future treatments. No new drugs are being tes…
Sponsor: Glycomine, Inc. • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC